Research of cGMP- and cAMP-dependent intracellular signaling systems in the insulin-mediated regulation of platelets aggregation activity in patients with heart failure and metabolic disturbances
https://doi.org/10.20538/1682-0363-2012-6-76-81
Abstract
Data of the study of cGMP- and cAMP-dependent intracellular signaling systems in the insulin-mediated regulation of the platelet aggregation activity in 25 patients with DM2 and heart failure are presented. 15 healthy volunteers were recruited as a control group. To estimate cAMP- and cGMP-dependent intracellular signaling systems in the realization of insulin antiaggregational effect we used 3-isobutyl-1-methyl-xanthine — inhibitor of the phosphodiesterase V and IV, forskolin — stimulator of adenylate cyclase, zaprinast — specific inhibitor of the phosphodiesterase V. Modifiers of the adenylate cyclase/cAMP system — IBMX and forskolin — had the most prominent effect on the reduction of the aggregation of the isolated platelets.
About the Authors
O. N. Ogurkova
НИИ кардиологии СО РАМН, г. Томск
Russian Federation
Russian Federation
T. Ye. Suslova
НИИ кардиологии СО РАМН, г. Томск
A. V. Sitoshevsky
НИИ кардиологии СО РАМН, г. Томск
O. A. Koshelskaya
НИИ кардиологии СО РАМН, г. Томск
References
1. Габбасов З.А., Попов Е.Г., Гаврилов И.Ю. // Лаборатор-ное дело.1989. № 10. С.15—18.
2. Шитикова А.С. Тромбоцитарный гемостаз. СПб., 2000. 227 с.
3. Banga J.D., Sixma J.J. Diabetes mellitus, vascular disease and thrombosis // Clin. Haematol. 2001. V. 15, № 2. P. 465—492.
4. Bedard S., B. Marcotte Insulin inhibition iNOS in the skelet muscle cell // Diabetologia. 2008. V. 12. P. 125—129.
5. Betteridge D.J., El Tahir K.E., Reckless J.P., Williams K.I. Platelets from diabetic subjects show diminished sensitivity to prostacyclin // Eur. J. Clin. Invest. 1992. V. 12. P. 95—398.
6. DeFronzo R.A., Ferranini E. Insulin resistance: A multifac-eted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular dise¬ase // Diabetes Care. 2001. V. 14. P. 173—194.
7. Dode-Boger S.M, Boger R.H,. Galland A, Frolich J.C. Dif-ferential inhibition of human platelet aggregation and throm-boxane A2 formation by L-arginine in vivo and in vitro // Naunyn-Schmiedeberg archives of pharmacology. 1998. V. 357, № 4. P. 143—150.
8. Gresele P., Page C., Fuster V. et al. Platelets. Cambridge, United Kingdom: Cambridge Academy Press. 2002.
9. Harrison H.E., Reece A.H., Johnson M. Effect of insulin treatment on prostacyclin in experimental diabetes // Dia-betologia. 1980. V. 18. P. 65—68.
10. Inada H., Shindo H., Tawata M., Onaya T. cAMP regu-lates nitric oxide production and ouabain sensitive Na+, K+-ATPase activity in SH-SY5Y human neuroblastoma cells // Diabetologia. 2008. V. 41, № 3. P. 1451—1458.
11. Kutti J., Wadenvik H., Henestam B., Stenstrom G. Evalua-tion of platelet reactivity in diabetes mellitus // Acta Med. Scand. 1986. V. 219. P. 195—199.
12. Rupprecht H.-J. Adenosine diphosphate receptor antagonists: from pharmacology to clinical practice // Europ. Heart J. 2000. V. 2, № E. P. 1—5.
13. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism // Nature. 2001. V. 414. P. 799—806.
14. Serebruany V.L., McKenzie M.E., Meister A.F. et al. Failu-re of Platelet Parameteres and Biomarkers to Correlate Plate-let Function to Severity and Etiology of Heart Failure in Pa-tients Enrolled in the EPCOT Trial // Pathophysiol Haemost Thromb. 2002. V. 32. P. 8—15.
15. Trovati M., Anfossi G., Cavalot F. et al. Insulin directly re-duces platelet sensitivity to aggregating agents. Studies in vitro and in vivo // Diabetes. 2001. V. 37, № 6. P. 780—786.
16. Udvardy M., Pfliegler G., Rak K. Platelet insulin receptor determination in noninsulin dependent diabetes mellitus // Ex-perientia. 2000. V. 41. P. 422—423.
Review
For citations:
Ogurkova O.N., Suslova T.Ye., Sitoshevsky A.V., Koshelskaya O.A. Research of cGMP- and cAMP-dependent intracellular signaling systems in the insulin-mediated regulation of platelets aggregation activity in patients with heart failure and metabolic disturbances. Bulletin of Siberian Medicine. 2012;11(6):76-81. (In Russ.) https://doi.org/10.20538/1682-0363-2012-6-76-81
Views:
1121
Email this article 